MAPT and Alzheimer disease: The classification differentiates fluid biomarkers from molecular (PET) imaging biomarkers, replaces total tau with NfL as the ‘N’ biofluid biomarker, and includes three new biomarker categories to incorporate inflammatory/immune mechanisms, and two common non-AD co-morbidities, vascular brain injury and synucleinopathy (25).